Introduction

On April 9, 2026, China's National Medical Products Administration (NMPA) approved two additional indications for Hanlikang® (rituximab) in non-Hodgkin's lymphoma (NHL), making it the first biosimilar in China to fully cover all approved indications of the originator drug. This development is significant for pharmaceutical manufacturers, global procurement agencies, and healthcare providers, as it signals China's biosimilars' growing alignment with international standards in clinical applicability, regulatory compliance, and reimbursement pathways.

Event Overview

The NMPA granted approval to Henlius' Hanlikang® for two new NHL indications on April 9, 2026. This marks the completion of its indication coverage, matching the originator rituximab's approved uses in China. The biosimilar is now positioned as a cost-effective alternative for global supply chains.

Impact on Sub-Sectors

Global Pharmaceutical Procurement

International buyers and distributors may now consider Hanlikang® as a viable alternative due to its full indication coverage and regulatory compliance. This could reshape procurement strategies, particularly in price-sensitive markets.

Biosimilar Manufacturers

Competitors in the biosimilar space should note the accelerated regulatory pathway demonstrated here. The approval sets a precedent for comprehensive indication approvals in China's biosimilar market.

Healthcare Providers

Hospitals and clinics in price-constrained systems may find expanded access to rituximab therapies through this biosimilar option, potentially affecting treatment protocols.

Key Considerations for Stakeholders

Monitor Regulatory Alignment

Track how NMPA's biosimilar approval patterns may influence other jurisdictions' acceptance of Chinese biosimilars.

Evaluate Supply Chain Integration

Assess the stability and scalability of Chinese biosimilar production for global distribution networks.

Review Reimbursement Policies

Payers should examine how this development might affect formulary inclusion and pricing structures for rituximab products.

Industry Perspective

From an industry standpoint, this approval represents more than just another product indication - it demonstrates China's biosimilar regulatory system reaching maturity. While the immediate impact will be felt in NHL treatment access, the longer-term significance lies in establishing China as a reliable source of complex biologics. However, actual market penetration will depend on post-approval factors including production capacity and international recognition.

Conclusion

The NMPA's approval completes Hanlikang®'s clinical profile, positioning it as a comprehensive alternative to originator rituximab. For the industry, this serves as both a concrete development in biosimilar availability and a signal of China's growing capabilities in biologic manufacturing. Stakeholders should view this as part of an ongoing trend rather than an isolated event.

Source

National Medical Products Administration (NMPA) announcement, April 9, 2026. Further developments in international recognition and market adoption require continued monitoring.